Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: Direct evidence for enhanced platelet reactivity in vivo

doi:10.1016/0002-9149(81)90065-5

The American Journal of Cardiology

Volume 48, Issue 3, September 1981, Pages 395-402

https://doi.org/10.1016/0002-9149(81)90065-5 Get rights and content

Abstract

Levels of beta thromboglobulin, a platelet-specific protein, in platelet-poor plasma from peripheral venous samples of patients with acute myocardial ischemia were measured in order to obtain direct evidence for enhanced platelet reactivity in vivo in these patients and to determine the value of beta thromboglobulin assay in studying platelet reactivity in patients with ischemic heart disease.

The normal beta thromboglobulin concentration in peripheral venous plasma, determined from normal volunteers and patients without known ischemic heart disease or disorders associated with enhanced platelet destruction (control group without platelet destruction), was 30.0 ± 12.6 ng/ml (mean ± standarddeviation) (range 10 to 59). The mean beta thromboglobulin level in hospitalized patients with chest pain judged not to be due to acute myocardial ischemia was 33.7 ± 12.0 (range 11 to 65). Patients with deep venous thrombosis, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura and idiopathic thrombocytopenic purpura provided a control group of patients with enhanced platelet destruction; the beta thromboglobulin level in this group was 131.0 ± 12.6 ng/ml (range 38 to 250).

Elevated beta thromboglobulin levels were observed in 4 (16 percent) of 25 patients with stable angina pectoris (mean 45.0 ± 22.6 ng/ml, range 22 to 125), in 23 (59 percent) of 39 patients with unstable angina pectoris (mean 83.2 ± 73.7 ng/ml, range 14 to 910) and in 12 (80 percent) of 15 patients with acute myocardial Infarction (mean 118.5 ± 66.2 ng/ml, range 30 to 420) on one or more occasions during hospitalization. The mean values of patients with platelet destruction in the control group (p <0.001), patients with acute myocardial infarction (p <0.005) and patients with unstable angina pectoris (p <0.025) were significantly elevated with respect to values in patients without platelet destruction in the control group. The beta thromboglobulin levels of patients with acute myocardial infarction generally remained elevated during the first 3 to 4 hospital days.

Elevation of beta thromboglobulin levels in patients with acute myocardial ischemia provides direct evidence for enhanced platelet reactivity in these patients. However, the temporal relation of the elevated beta thromboglobulin values with clinical deterioration was imprecise, so that it can not be determined from this study whether the enhanced platelet reactivity was a cause or an effect of the acute myocardial ischemia in these patients. Assay of beta thromboglobulin appears to be suitable as an indicator of enhanced platelet reactivity in patients with ischemic heart disease. Its use obviates many of the difficulties in interpretation of the various in vitro analyses of platelet function and platelet survival studies.

References (44)

HJ Weiss
Antiplatelet drugs: a new pharmacologic approach to the prevention of thrombosis
Am Heart J
(1976)
MA Packham et al.
Clinical pharmacology of platelets
Blood
(1977)
AI Schafer et al.
The role of platelets in thrombotic and vascular disease
Prog Cardiovasc Dis
(1979)
J Dawes et al.
The release, distribution, and clearance of human beta-thromboglobulin and platelet factor 4
Thrornb Res
(1978)
CA Ludlam et al.
The release of a human platelet specific protein measured by a radioimmunoassay
Thromb Res
(1975)
RL Nachman
Immunologic studies of platelet protein
Blood
(1965)
MG Davey et al.
Release reactions of human platelets induced by thrombin and other agents
Biochim Biophys Acta
(1968)
S Moore et al.
The isolation and characterization of a platelet-specific beta-globulin (beta-thromboglobulin) and the detection of antiurokinase and antiplasmin released from thrombin-aggregated washed human platelets
Biochim Biophys Acta
(1975)
CA Ludlam et al.
New rapid method for diagnosis of deep venous thrombosis [letter]
Lancet
(1975)
JR O'Brien et al.
Beta-thromboglobulin and heparin-neutralizing activity test in clinical conditions
Lancet
(1977)

CWG Redman et al.

Plasmabeta-thromboglobulin in pre-eclampsia [letter]

Lancet

(1977)

AW Burrows et al.

Plasma-thromboglobulin concentrations in diabetes mallitus

Lancet

(1978)

B Pugh et al.

Unstable angina pectoris: a randomized study of patients treated medically and surgically

Am J Cardiol

(1978)

JV Nixon et al.

Submaximal exercise testing after unstable angina

Am Heart J

(1980)

JI Had

Role of blood platelets in coronary artery disease

Am J Cardiol

(1979)

Sulfinpyrazone in the prevention of sudden death after myocardial infarction

N Engl J Med

(1980)

Persantine and aspirin in coronary heart disease

Circulation

(1980)

A randomized, controlled trial of aspirin in persons recovered from myocardial infarction

JAMA

(1980)

KL Kaplan et al.

Radioimmunoassay of platelet factor 4 and beta-thromboglobulin: development and application to studies of platelet release in relation to fibrinopeptide A generation

Br J Haematol

(1978)

AE Bolton et al.

Three approaches to the radioimmunoassay of human beta-thromboglobulin

Br J Haematol

(1976)

J Salmon et al.

Study of platelet antigens and especially of fibrinogen

Thromb Diath Haemorrh

(1958)

G Sokal

Morphological study of the blood platelets and of viscous metamorphosis using antifibrinogen and antiplatelet fluorescent antiserums

Acta Haematol (Basel)

(1962)

Cited by (113)

Individual variations in platelet reactivity towards ADP, epinephrine, collagen and nitric oxide, and the association to arterial function in young, healthy adults
2019, Thrombosis Research
Citation Excerpt :
Interesting, collagen can induce secretion of dense- and alpha-granule without causing full aggregation, which could lead to a hypersecretory phenotype of platelets [27]. Increased platelet reactivity has previously been recorded in hypertension [28], angina pectoris and myocardial infarction [29,30] where administration of NO-donating drugs can restore the platelet reactivity to normal levels [31]. Prostacyclin and NO released from the healthy endothelium reduce the platelet aggregatory ability.
Platelet aggregation and secretion can be induced by a large number of endogenous activators, such as collagen, adenosine diphosphate (ADP) and epinephrine. Conversely, the blood vessel endothelium constitutively release platelet inhibitors including nitric oxide (NO) and prostacyclin. NO and prostacyclin are also well-known vasodilators and contribute to alterations in local blood flow and systemic blood pressure.
In this study we investigated individual variations in platelet reactivity and arterial functions including blood pressure and flow-mediated vasodilation (FMD) in 43 young, healthy individuals participating in the Lifestyle, Biomarkers and Atherosclerosis (LBA) study. Platelet aggregation and dense granule secretion were measured simultaneously by light transmission and luminescence. FMD was measured with ultrasound.
The platelet function assay showed inter-individual differences in platelet reactivity. Specifically, a sub-group of individuals had platelets with an increased response to low concentrations of ADP and epinephrine, but not collagen. When the NO-donor S-nitroso-N-acetyl-DL-penicillamine (SNAP) was combined with high doses of these platelet activators, the results indicated for sub-groups of NO-sensitive and NO-insensitive platelets. The individuals with NO-sensitive platelets in response to SNAP in combination with collagen had a higher capacity of FMD of the arteria brachialis.
Platelet reactivity towards ADP, epinephrine and NO differs between young, healthy individuals. Some individuals have a more effective response towards NO, both in the aspect of platelet inhibition ex vivo, as well as vasodilation in vivo.
The utility of inflammation and platelet biomarkers in patients with acute coronary syndromes
2018, Saudi Journal of Biological Sciences
Citation Excerpt :
The evaluation of β-TG, however regarding the concentration of protein tested, so far has been conducted only by Smitherman et al. (1981). According to authors the β-TG levels obtained in subjects with acute myocardial infarction were increased in general within the first 3–4 days of hospitalization (Smitherman et al., 1981). Current study indicated that the evaluation of β-TG activity may be a suitable parameter to grade the platelet activity in ACS patients.
Thrombotic and inflammatory mechanisms are involved in the pathophysiology of acute coronary syndrome (ACS). The aim of the study was the evaluation of inflammation (white blood cells count/WBC, C-reactive protein/CRP, interleukin-6/IL-6) and platelet (platelet count/PLT, mean platelet volume/MPV, large platelet/LPLT, beta-thromboglobulin/β-TG) biomarkers in the groups of ACS patients depending on the severity of signs and symptoms and compared to controls without coronary artery disease.
The study group included 93 patients categorized into 3 subgroups depending on the severity of signs and symptoms of ACS. PLT, MPV, LPLT, and WBC were determined on hematological analyzer, IL-6 and β-TG were measured using the ELISA method.
In the whole group of ACS patients WBC, CRP, IL-6, MPV, and β-TG were significantly higher as compared to controls. Analyzing the inflammation and platelet biomarkers depending on the severity of signs and symptoms in comparison to controls, statistically significant differences for above-mentioned parameters were also found. There were no significant differences between the advancement of coronary artery changes and inflammation as well as platelet parameters, except for CRP concentrations. The AUCs for all inflammation parameters tested were similar, however the highest AUCs showed WBC and CRP. Among platelet parameters the highest AUC revealed β-TG.
Markers of inflammation and platelet activation may be associated to myocardial ischemia and myocardial injury. WBC, CRP and IL-6 as inflammation parameters and MPV and β-TG as platelet biomarkers may be useful indicators of the presence of coronary artery disease.
Peripheral Vascular Disease
2013, Platelets
Peripheral Vascular Disease
2012, Platelets, Third Edition
Peripheral vascular disease
2007, Platelets
Peripheral vascular disease
2006, Platelets, Second Edition

View all citing articles on Scopus

^☆: This study was supported in part by the Medical Research Service of the Veterans Administration, Washington, D.C., the Eugene B. McDermott Foundation, Dallas, Texas, Grants CA23115 and CA18132 from the National Cancer Institute, Washington, D.C. and Grant HL-17669 from the Ischrmic Heart Center Specialized Center of Research, National Institutes of Health, Bethesda, Maryland.

View full text

Clinical studyElevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: Direct evidence for enhanced platelet reactivity in vivo☆

Abstract

Am Heart J

Blood

Prog Cardiovasc Dis

Thrornb Res

Thromb Res

Blood

Biochim Biophys Acta

Biochim Biophys Acta

Lancet

Lancet

Lancet

Lancet

Am J Cardiol

Am Heart J

Role of blood platelets in coronary artery disease

Am J Cardiol

Sulfinpyrazone in the prevention of sudden death after myocardial infarction

N Engl J Med

Persantine and aspirin in coronary heart disease

Circulation

A randomized, controlled trial of aspirin in persons recovered from myocardial infarction

JAMA

Radioimmunoassay of platelet factor 4 and beta-thromboglobulin: development and application to studies of platelet release in relation to fibrinopeptide A generation

Br J Haematol

Three approaches to the radioimmunoassay of human beta-thromboglobulin

Br J Haematol

Study of platelet antigens and especially of fibrinogen

Thromb Diath Haemorrh

Morphological study of the blood platelets and of viscous metamorphosis using antifibrinogen and antiplatelet fluorescent antiserums

Acta Haematol (Basel)

Clinical study
Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: Direct evidence for enhanced platelet reactivity in vivo☆